Pharmaceutical

Agilent agrees to acquire BIOVECTRA for $925m

Agilent Technologies has announced a definitive agreement for the acquisition of Canadian CDMO BIOVECTRA in a deal worth $925m.

Jul 24, 2024 - 04:00
Agilent agrees to acquire BIOVECTRA for $925m
Agilent Technologies has announced a definitive agreement for the acquisition of Canadian CDMO BIOVECTRA in a deal worth $925m.
Read the original article

Tags:

Previous Article

Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Se...

Next Article

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: DOJ, FTC primed for more aggressive scrutiny of health care mergers

STAT+: DOJ, FTC primed for more aggressive scrutiny of ...

Jul 20, 2023

Amendments Set to Clear Ambiguity

Amendments Set to Clear Ambiguity

Apr 16, 2023

How an immunological Trojan horse could treat disease

How an immunological Trojan horse could treat disease

Jan 30, 2024